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A nucleic acid strand displacement system for the
multiplexed detection of tuberculosis-speciﬁc
mRNA using quantum dots†
H. D. Gliddon,‡a,b P. D. Howes,‡a M. Kaforou,b M. Levinb and M. M. Stevens*a
The development of rapid, robust and high performance point-of-care diagnostics relies on the advance-
ment and combination of various areas of research. We have developed an assay for the detection of mul-
tiple mRNA molecules that combines DNA nanotechnology with ﬂuorescent nanomaterials. The core
switching mechanism is toehold-mediated strand displacement. We have used ﬂuorescent quantum dots
(QDs) as signal transducers in this assay, as they bring many beneﬁts including bright ﬂuorescence and
multiplexing abilities. The resulting assay is capable of multiplexed detection of long RNA targets against a
high concentration of background non-target RNA, with high sensitivity and speciﬁcity and limits of
detection in the nanomolar range using only a standard laboratory plate reader. We demonstrate the
utility of our QD-based system for the detection of two genes selected from a microarray-derived tuber-
culosis-speciﬁc gene expression signature. Levels of up- and downregulated gene transcripts comprising
this signature can be combined to give a disease risk score, making the signature more amenable for use
as a diagnostic marker. Our QD-based approach to detect these transcripts could pave the way for novel
diagnostic assays for tuberculosis.
The ‘-omics’ areas of biomedical research (transcriptomics,
genomics, proteomics, metabolomics and lipidomics) are
revealing ever more complex and subtle relationships between
biomolecular signatures and health status. Such studies are
identifying biomarkers with the potential to be developed into
diagnostic tests. However, the detection of these biomarkers is
often beyond the capabilities of current diagnostic techno-
logies. The future of molecular diagnostics relies on techno-
logical developments in various research areas to create
diagnostics that can make use of those biomarkers that are too
hard to detect or otherwise beyond the reach of current diag-
nostic approaches in a clinical setting.
A vast amount of information concerning the health of an
individual can be derived from studying their blood, and in
particular its biomolecular make-up, which changes with
health status. Studying the molecular content of blood (and
other physiological samples) for signatures of biomolecular
change is the principal behind molecular diagnostics, an
approach that can yield vital information with minimal invasive-
ness. Of course molecular diagnostics is a firmly established
art, and techniques such as enzyme-linked immunosorbent
assays (ELISAs) for proteins and polymerase chain reaction
(PCR)-based assays for nucleic acids oﬀer viable ways of detect-
ing and quantifying molecular biomarkers of disease in a clini-
cal setting. There are however some impediments with these
and related technologies. Critically, they are slow and cumber-
some, and although medical practice can work with this in
some situations, in others (such as time-dependent care and in
resource-limited settings) they are a critical road block.
DNA nanotechnology, where nucleic acids are used to build
structural and/or mechanistic systems, has emerged as an area
that could prove transformative in the way we detect genomic
biomarkers, both in vitro and in cell studies.1–4 Of specific
interest here is a process called ‘toehold-mediated strand dis-
placement’, which has become an important mechanism upon
which to base dynamic DNA systems.5 Here, an incoming
invading strand binds to an overhanging toehold region of a
DNA duplex, then proceeds to displace the incumbent DNA
strand by branch migration. The displacement is driven
forward by the net gain in paired bases as the system naturally
moves towards a lower energy configuration.6 This mechanism
has been used in various systems related to DNA nanotechno-
logy, including DNA logic circuits,7 mechanical structures,8 and
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nanomachines.9 Importantly, strand displacement mechanisms
have been used to good eﬀect in biosensing systems, and have
been used to detect DNA,10 RNA,11 proteins and small mole-
cules.12 Biosensing mechanisms must undergo a chemical or
physical change upon interaction with their specific target, but
must not respond to interaction with any non-target species. By
nature of the Watson-Crick base pairing of the toehold and the
target nucleic acid, toehold-mediated strand displacement is
highly specific to its target. Furthermore, the inherent action of
strand displacement leads to a structural change that can
readily form the basis of a switching event. The switching event
can either lead directly to a signal change itself,12 or it can
initiate a downstream event that leads to a signal change.11
Another research area that has contributed to a push
towards advanced molecular diagnostics is nanoparticle-based
biological sensors.13,14 A key advantage of using nanoparticles
as signal transducers is the ability to construct homogeneous
(i.e. completely solution phase) assays, which typically oﬀer
greatly improved reaction kinetics and sensitivity compared to
heterogeneous (i.e. surface-based) assays. Fluorescent in-
organic semiconductor nanoparticles (so-called ‘quantum
dots’, QDs)15 have been proven as eﬀective signal transducers
in highly sensitive biosensing systems.13,16–22 QDs oﬀer extre-
mely high fluorescence brightness, narrow emission and
broad absorption spectra, large Stokes shift, high quantum
yields and excellent resistance to photodegradation.23 As their
emission spectra are extremely narrow, tunable by particle size
(larger QDs are redder, smaller ones bluer), and absorbance
spectra very wide, a mixed population of QDs can be excited
with a single high-energy excitation source, and will emit in
well-defined and spectrally separate emission bands. Linking
these diﬀerent colors of QDs to diﬀerent target biomolecules
in solution allows for multiplexed detection.24–31
Critically for the construction of QD biosensors, their emis-
sion characteristics (emission intensity, spectral profile or
polarization) can be altered in response to interaction with
target biomolecules in solution, creating the basis of a biosen-
sing system. This is typically based on resonance energy trans-
fer (RET) from the QD core to an external energy acceptor such
as an organic molecular dye or a gold nanoparticle.32 A key
task then is to develop mechanisms that can take advantage of
their extraordinary properties. QDs can be readily conjugated
with biomolecules using a large number of diﬀerent methodo-
logies,33,34 which allows us to build biomolecular-based
sensing mechanisms directly onto compact QDs in solution.
A large variety of homogeneous QD assays for nucleic acid
detection have been developed to date.35,36 These predomi-
nantly rely on sandwich-like detection mechanisms, where a
dye-labeled signal probe is brought into close proximity of the
QD surface by the formation of a surface-bound duplex.35
However, such mechanisms may suﬀer from steric hindrance
and reduced reaction kinetics due to overloading nanoparticle
surfaces, and the dye-QD separation distance is relatively large
which is a significant drawback in such systems.
In this work we have combined the advantages of toehold-
mediated strand displacement systems with those of QDs to
produce a novel multiplexed assay for the detection of RNA.
We demonstrate the eﬃcacy of this system by detecting syn-
thetic mRNA analogues as biomarkers of tuberculosis (TB)
infection.
The control of TB is severely hindered by a lack of eﬀective
diagnostic tests. Current diagnosis depends on analysis of
clinical and radiological signs, as well as other diagnostic
tests, which are either insensitive, unspecific or time-consum-
ing, leading to missed diagnoses and poor patient outcomes.
In much of sub-Saharan Africa, HIV prevalence is also high,
further complicating the diagnosis of TB. In patients co-
infected with HIV and TB, the probability of developing extra-
pulmonary TB is increased,37 meaning sputum (mucus from
the lower airways) samples and chest X-rays are of little use in
diagnosing the disease. Unfortunately, most TB diagnostic
assays in use today rely on sputum as a clinical sample. A
more useful clinical sample would be whole blood, specifically
purified RNA from whole blood.
Detection of mRNA is potentially a very powerful way of
diagnosing a range of diseases. Studying gene expression pat-
terns using microarray analysis has led to a deeper under-
standing of the pathogenesis of a number of diseases, as well
as the identification of blood or tissue transcriptomic pro-
files.38,39 However, the use of these transcript signatures as diag-
nostic biomarkers has been limited by the large number of
transcripts that comprise gene expression signatures and the
technical and cost restraints required to measure gene
expression. In an eﬀort to reduce this complexity, a recent study
successfully identified much reduced gene signatures for TB.40
A key advance in this work was the development of a ‘disease
risk score’ (DRS) to simplify the analysis of the microarray intensi-
ties, where the summed intensities of downregulated genes were
subtracted from the summed intensities of the upregulated
genes. This allowed a single number to be calculated for each
patient that indicated the probability that they had TB with
high sensitivity and specificity, making the gene signatures
much more amenable for use as biomarkers in diagnostic
assays.
We selected two genes from the 44-gene signature for dis-
tinguishing TB from other diseases reported by this study to
use as proof of principle biomarkers for our assay. These
genes, GBP6 and TMCC1, are up- and downregulated respect-
ively in patients with TB compared to patients with other dis-
eases with similar clinical presentation.40
Our work addresses some key design challenges that must
be overcome to realize eﬀective multiplexed QD-based assays
for detecting long nucleic acid targets as part of minimal gene
panels. These are:
1. For large target molecules (e.g. long DNA/RNA strands),
it is advantageous to have the target substrate decoupled from
the nanoparticle surface, as steric hindrance of several large
molecules interacting with a single nanoparticle may restrict
reaction kinetics and curtail the advantages of colloidal
systems.
2. For multiplexed measurements with QDs, each detection
mechanism needs to be orthogonal such that a specific target
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interacts with a specific species of QD, and the mechanisms
do not cross-react.
3. For Förster resonance energy transfer (FRET)-based
sensing mechanisms, it is imperative to minimize the separ-
ation between the QD core and the FRET acceptor molecule.
This is diﬃcult to achieve with sandwich-type approaches.
4. For detection of nucleic acids in complex biological solu-
tions (e.g. against a high concentration background of nucleic
acids), where non-target interferent biomolecules are present
in a vast abundance compared to any target molecules, it is
challenging to create nanoparticle-based biosensing mecha-
nisms that work eﬀectively and avoid non-specific interactions.
5. Homogenous systems, where no washing or purification
steps are required, are highly desirable to reduce the time and
diﬃculty of running an assay. However this is challenging as
detection and signaling must occur in complex matrices.
The QD-based assay described herein is capable of multi-
plexed detection of long synthetic RNA targets against a high
concentration of background non-target RNA, with high sen-
sitivity and specificity, and a low limit of detection (LOD),
using a standard laboratory plate reader. Furthermore, the
target RNA does not come into contact with the QDs, long
RNA targets can be detected, orthogonal components allow
multiplexing, QD–acceptor distance is minimized and no
washing steps are required. We demonstrate the utility of our
QD-based system for the detection of two genes selected from
a TB-specific gene expression signature.
Materials and methods
Materials
Nuclease-free water (not DEPC treated), Qdot655 and Qdot525
ITK-streptavidin conjugate kits were purchased from Life
Technologies. All other reagents were purchased from Sigma
Aldrich, UK. Quencher probes (Qprobes) were purchased from
IBA Life Sciences, Germany. All other oligonucleotides were
purchased from Integrated DNA Technologies Inc., Belgium.
All oligonucleotides were HPLC purified and freeze-dried by
the supplier. Oligonucleotides were used as provided and dis-
solved in nuclease-free water to give stock solutions of 20 µM
(probes) or 50 µM (targets). The sequences of the oligonucleo-
tides used are detailed in Table 1. All assays were carried out
in black polystyrene half volume Corning® 96 Well Plates
(Sigma) and fluorescence emission was recorded using an
EnSpire® Multimode Plate Reader (Perkin Elmer).
Kinetics of strand displacement
QProbe and T* (the detection complex), mixed at a 1 : 1 ratio,
were first hybridized in Tris buﬀer (10 mM Tris-HCl, 150 mM
NaCl, 5 mMMgCl2, pH 7.4) and were subjected to a temperature
gradient (80 °C for 5 minutes, down to 25 °C, falling by 1 °C
every 60 seconds). Then 8 pmoles of each hybridization reaction
was added to a well, with SYBR Safe (Life Technologies) added
to a final concentration of ×2.5 in the Tris buﬀer. One molar
equivalent of target was added to make a final concentration of
80 nM target and the total volume was 100 μL. Fluorescence
emission was read following excitation at 480 nm.
Analysing the kinetics of QProbe–CProbe hybridization
QDs were functionalized with a Capture Probe (Cprobe) : QD ratio
of 30 : 1 for TMCC1 and 20 : 1 for GBP6, in borate buﬀer (50 mM
borate, 150 mM NaCl, 0.01 % BSA (w/v), pH 8.3) for 60 minutes at
room temperature in the dark. One molar equivalent of QProbe
was added, bringing the final volume to 50 μL. Fluorescence was
monitored for 70 minutes with excitation at 405 nm.
Assay protocol
Component preparation. Hybridization of the detection
complex (T* and QProbe) at 1 : 1 ratio was performed in Tris
buﬀer. Solutions were heated to 80 °C for 5 minutes and then
subjected to a temperature gradient to 25 °C, falling by 1 °C
every 60 seconds to achieve maximum hybridization. QDs were
functionalized with CProbe (at a CProbe : QD ratio of 30 : 1 for
Table 1 The oligonucleotides used in this study. Mismatches in BP are underlined. Toehold region of T* in italics. Recognition sequence/region of
complementarity of target/competitor shown in bold
Name
Nucleic
acid type Sequence Modifications Length
GBP6 T RNA GCU UAU UAG AGG AUA UCA GUG CCU GGC CCA CAU GAG AGA ACA GAU CCA
UAC ACA CUU UGA AAA ACU UUG U
— 70
GBP6 T* DNA TCA AAG TGT GTA TGG ATC TGT TCT CTC ATG TGG GCC AGG CAC TGA TAT CC — 50
GBP6 BP DNA AAT CAA AGT C̲TG TAT GGA TG̲T GTT CTC T Biotin at 5′ 28
GBP6 QProbe DNA AGA GAA CAG ATC CAT ACA CAC TTT GA DYQ1 at 3′ 26
TMCC1 T RNA UGU AAU CUG ACA CAG GCA AAA UUA UGG UUC CCA CAC CCC AAC CCC AAA
UGA AAC CUG GGA UUU UGA AUG U
— 70
TMCC1 T* DNA TCC CAG GTT TCA TTT GGG GTT TGG GTG TGG GAA CCA TAA TTT TGC CTG TG — 50
TMCC1 BP DNA AAT CCC AGC̲ TTT CAT TTG C̲GG TTT GGG T Biotin at 5′ 28
TMCC1 QProbe DNA ACC CAA ACC CCA AAT GAA ACC TGG GA DYQ2 at 3′ 26
GBP6 T* Comp DNA TGG TGG CCG GGT AGG ATG ATC CTG AGC ATC AGT GCC TGG CCC AGT ACA
GCT TGA GAG ACC CCC TTC ACT C
— 70
GBP6 QProbe Comp DNA TGG CTC CCC GCC CCT CGG TCT CCA CGT GGT GTA TGG ATC TGT GGT
CAT TGT CCC TCT GCA GAA TAA AGA T
— 70
GBP6 BP Comp DNA GGA CTA CGT CAA CAA GGA GCT GGC CCT GCA CAT CCA TAC AGA CAT
CGA CAG CCA GGG TAT CTT CTT CAC A
— 70
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TMCC1 and 20 : 1 for GBP6) in borate buﬀer for 60 minutes at
room temperature in the dark.
Assay. The detection complex (hybridized T*-QProbe) was
added to the target solution (Tris buﬀer) to bring the assay
volume to 20 µL. Following incubation at room temperature
for 60 minutes, QD-CProbe was added (so that the resulting
CProbe : QProbe ratio was 1 : 1) to bring the total assay volume
to 25 µL with a final QD concentration of 4 nM. Fluorescence
emission was recorded using an excitation wavelength of
405 nm. Error bars in figures are calculated from technical
triplicates. Dose–response curves were plotted in Origin 2015
(Origin Lab), and fitted using the dose–response function.
Purification of RNA from whole blood
Whole blood taken from healthy volunteers was collected in
PAXgeneTM tubes and stored at −80 °C. PAXgene™ Blood RNA
Extraction Kits (Qiagen) were used to extract RNA before ana-
lyzing concentration and purity on a Nanodrop 1000 Spectro-
photometer (Thermo Scientific).
Ethics statement
Healthy Volunteers from the Department of Medicine, Imper-
ial College London were recruited under an Imperial College
Healthcare Tissue Bank (ICHTB) Human Tissue Act License
(12 275) and a Research Ethics Committee Wales approval
(12/WA/0196). Tissue Bank Application Number Project
R13062; exploring genetic and cellular immune responses in
children with life threatening infections. Written information
was provided and all participants provided written consent.
Results and discussion
Assay concept
The core concept of our assay design is that the target nucleic
acid does not come into direct contact with the QD (see
Scheme 1). Instead, there is an intermediate DNA construct
(termed the ‘detection complex’) that interacts directly with
the target RNA, releasing a short quencher-labeled DNA probe
(termed the ‘quencher probe’, QProbe) that subsequently
binds to the QD. The detection complex consists of a 50mer
DNA sequence (termed the anti-target or T*) that is comp-
lementary to a corresponding 50mer recognition sequence on
the target RNA. Hybridized with this T* strand is the shorter
26mer QProbe, yielding a remaining 24mer ssDNA region that
acts as the toehold for strand displacement upon binding to
the RNA target. Additionally, these complexes are highly stable
due to their relatively high Tm (ca. 65 °C for GBP6 and 73 °C
for TMCC1, at 150 mM NaCl) therefore it should only dis-
sociate in the presence of its specific target. The first step of
the assay is to incubate the detection complex with the target,
which induces strand displacement and yields a population of
QProbes that are unbound in solution (Scheme 1a). In a
second step, a population of QDs were functionalized with
ssDNA surface probes (we term ‘capture probes’, CProbes) that
are complementary to the QProbes (Scheme 1b). Specific
hybridization of the QProbe and CProbe brings the dye into
close proximity of the QD and allows FRET to occur from the
QD (donor) to the dye (acceptor). The decrease in fluorescence
of the QD is then the signal that the target has been detected
(Scheme 1c). From a mixed population of QDs (Scheme 1d),
simultaneous measurement of non-overlapping emission
spectra can be made corresponding to diﬀerent target mRNAs,
which can then be converted into corresponding dose–
response relationships.
Melting temperatures for QProbe : CProbe hybridization
were reduced by incorporating two mismatches into each CProbe,
which reduced each Tm by approximately 10 °C (Fig. S1†). This
resulted in the QProbe preferentially binding to the T* over the
CProbe, reducing the likelihood of false positive results.
With reference to the key design challenges that we identi-
fied above, our assay exhibits the following advantages: (1) the
long RNA target does not come into direct contact with the
QD, which negates steric hindrance issues that could occur
with multiple long strand targets interacting at the surface of
the nanoparticle. (2) The target induced signaling cascade is
based purely on nucleic acid base pairing between comp-
lementary sequences, therefore many cascades can run in par-
allel without cross-reactivity. This makes the assay highly
suitable for multiplexed detection using multiple colors of QD.
Scheme 1 (a) The detection complex with and without presence of
target. (b) The QD in its ﬂuorescent and quenched state. (c) Illustrative
ﬂuorescence spectra of the QD in the unquenched and quenched state.
(d) Illustration of the multiplexed detection: a mixed population of QDs
yields distinct emission spectra from which dose–response relationships
can be derived with varying concentrations of target RNA.
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(3) The donor–acceptor (QD–quencher) distance is minimized
as the QProbe binds to the QD with the quencher at the proxi-
mal end of the CProbe : QProbe duplex, allowing for maximal
energy transfer and change in fluorescence signal per target
present in the system. Such an orientation of probe is diﬃcult
to obtain using common ‘sandwich’ approaches. We note here
that this distance could readily be decreased yet further using
QDs with more compact capping layers, such as thiolated
zwitterionic ligands.41 (4) As the signal cascade is based on
highly specific nucleic acid hybridization there is little inter-
ference from an abundant background of non-target RNA or
DNA. (5) This is a homogeneous two-step assay that requires
no washing or purification steps, and functions well even in a
background of non-target nucleic acids. Additionally – as there
is no need to wash or purify – the assay time is limited only by
the two incubation steps, which we show are both relatively
fast.
Component testing
The assay relies on two main mechanisms. The first is the
target-induced separation of the detection complex by toehold
induced strand displacement. The second is the liberated
QProbes binding to the QD. These two mechanisms were tested
separately before constructing and testing the final assay.
The QDs used in this work are coated with streptavidin (SA) to
allow facile conjugation with biotinylated DNA. Each streptavi-
din tetramer has four biotin binding sites, but their availability
on the QD surface is orientation-dependent. Additionally,
diﬀerent species of QD-SA conjugates are diﬀerent sizes and
therefore have varying capacities to bind biotin due to their
variations in surface area. As there are multiple quenchers
binding to a single QD, it is important to determine an upper
limit for the ratio of quencher to QD in terms of signal delta
for each additional quencher added i.e. we want to operate in a
region where each additional quencher still has a significant
quenching eﬀect on the QD. By pre-hybridizing the QProbe
and the CProbe, adding this into the QDs at increasing ratios
and observing the quenching of the QDs, we determined this
upper limit to be approximately 20 for QD525s and 30 for
QD655s (Fig. S2†). Therefore in the assay, ratios of CProbe to
QD were 20 : 1 for the QD525s and 30 : 1 for the QD655s. The
QD525s were paired with a DYQ1 quencher and the QD655s
were paired with a DYQ2 quencher.
The theoretical limit of detection (LOD) of the assay is
dependent on the QD fluorescence signal delta for binding a
given number of QProbes. Additionally the concentration of QDs
used is critical as there is direct linear proportionality between
the target concentration and the QD fluorescence response –
therefore the lower the concentration of QDs that can give a sig-
nificant and repeatable signal intensity on a given fluore-
scence reader (in this case a commercial plate reader) the
lower the ultimate LOD. We used a reaction volume of 25 μl and
a QD concentration of 4 nM. The theoretical LOD for the
quenching mechanism was determined by adding in an increas-
ing ratio of QProbe to a QD solution, and subtracting three stan-
dard deviations from the mean of the control (no QProbe). Here
we determined an LOD of 1.6 nM for QD525-DYQ1 (GBP6
QProbe detection) and 6.4 nM for QD655-DYQ2 (TMCC1 QProbe
detection). Plots and calculations are shown in Fig. S3.†
It is desirable for point-of-care applications to minimize
assay run time. As incubation steps can take up a significant
portion of assay time it is useful to have a thorough under-
standing of how long each reaction step needs in order to
reach completion to avoid unnecessary time loss. In this assay
there are two incubation steps: firstly the target addition to the
detection complex, and secondly the addition of the QDs to
the solution (to bind free QProbes). Two kinetic experiments
were conducted to characterize these steps. For the target–
detection complex step, the intercalating dye SYBR Safe was
used to follow the kinetics of toehold-mediated strand displa-
cement. When SYBR Safe is intercalated in dsDNA its fluo-
rescence intensity (FI) increases by ca. four orders of
magnitude, therefore it can be used to monitor the proportion
of dsDNA versus ssDNA in a given system. Here, the detection
complex – which contains 26 base pairs – was incubated with
SYBR Safe. When the target was added (at a molar ratio of 1 : 1,
target to detection complex), it displaced the QProbe and
formed a 50 bp dsDNA duplex with the T* strand. This
increase in total base pairs (24 per complex, ca. two-fold) led
to a two-fold increase in overall FI (Fig. 1a). For the GBP6
target, the displacement reaction went to completion after only
two minutes. For the TMCC1 target, displacement took slightly
longer, but went to completion after only five minutes. To
characterize the second incubation step, quencher probes were
added to their respective QDs (at a ratio of 20 : 1 for GBP6
QProbe : QD525 and 30 : 1 for TMCC1 QProbe : QD655), and
the fluorescence quenching of the QDs upon RET to the proxi-
mal acceptors was used to characterize the kinetics of this
reaction. For both the QD525s and the QD655s, maximal
quenching was reached after ca. 5 min (Fig. 1b). From these
two experiments it is shown that incubation steps of little over
5 min are required during the assay.
Full assay
The full assay was tested in two stages. Firstly, the two targets
were detected separately in monoplex assays and characterized
Fig. 1 (a) Kinetics of toehold-mediated strand displacement measured
with SYBR Safe, and (b) kinetics of Qprobe to QD binding (normalized to
control without Qprobe addition). GBP6 (open circles) and TMCC1
(closed circles) are represented.
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as individual assays. Secondly, in order to demonstrate multi-
plexing with this system, we combined the two assays and
showed that the two targets can be detected simultaneously in
a single solution.
The dose–response curves for the GBP6 and
TMCC1 monoplex assays are shown in Fig. 2. In both cases,
the QD fluorescence intensity (FI) is seen to decrease with
increasing target concentration, due to target-induced displa-
cement of QProbes and hybridization to the CProbe. Conduct-
ing experiments with higher resolution in the low target
concentration regime, we determine the LODs to be below
10 nM for detection of both GBP6 and TMCC1 synthetic RNA
targets (see Fig. S4†). As the response of the assays is sharp,
the saturation point of each system is above 70 nM, resulting
in a somewhat limited dynamic range. However, the assay
could be readily tuned across a much larger dynamic range for
specific targets by varying assay component concentrations
and ratios.
The point of inflection of the dose–response curve of
TMCC1 is shifted to a higher target concentration versus that
of GBP6. We ascribe this to enhanced stability of the TMCC1
detection complex compared to the GBP6 detection complex.
The melting temperature (Tm) of the TMCC1 detection
complex is 73 °C compared to 65 °C for the GBP6 complex,
making the strand displacement of the TMCC1 QProbe from
T* less energetically favorable than it is for GBP6. The kinetics
of strand displacement (Fig. 1a) show that strand displacement
is slower for the TMCC1 complex, which supports our asser-
tion that this complex is harder to disrupt than the GBP6
detection complex. Nevertheless, the detection mechanism is
shown to work in each case with a low LOD.
In order to demonstrate the potential for multiplexed analy-
sis using this assay, the monoplex assays were combined and
run simultaneously. Three conditions were explored for this
experiment, with either target present or both targets present.
Fig. 3a shows the response of the QD525 in the presence of
either and both targets. When GBP6 is present, the QD fluo-
rescence decreases in the same manner as the monoplex case.
Fig. 3b shows the response of the QD655 for the same cases,
and the QD fluorescence decreases as expected in the presence
of TMCC1. Crucially, both QDs show no response to the pres-
ence of the ‘other’ target, with both showing flat response
lines in Fig. 3a and b. This shows that there is no cross-reactiv-
ity in the system and that the two ‘cascades’ operate ortho-
gonally to one another. Fig. 2a shows the appearance of an
apparent ‘hook eﬀect’ in the GBP6 assay, which could be
caused by excess target RNA hybridizing to the CProbe, pre-
venting it from hybridizing to the QProbe and thus reducing
QD quenching. This could easily be overcome using multiple
assay mixes, each optimized for the detection of a specific
range of target concentrations.
Assay function against background RNA
Having shown that the assay mechanisms function well in
pure buﬀer (i.e. target RNA present with no competing non-
target RNA) we moved on to examine the behaviour of the
assay in a more complex solution. For optimal assay function,
it is imperative that non-target molecules in the solution do
not interfere with the assay. For nanoparticle-based assays,
such interference can cause false triggering or blocking of the
sensing mechanism, or can directly aﬀect the stability of the
nanoparticles, resulting in either false positive or false nega-
tives. In order to assess the resilience of our assay against
interference from non-target nucleic acids, the assay was run
in a solution containing 25 ng μL−1 concentration of RNA iso-
lated from whole blood (this represents 25% reaction volume
as standard yields are around 100 ng μL−1). This was designed
to replicate the scenario of detecting target RNA directly from
a total RNA isolation from whole blood. Fig. 3c and d shows
the results of this experiment, and it can be seen that the form
Fig. 3 Multiplexed assays for simultaneous GBP6 and TMCC1 detec-
tion. (a) The response the QD525/GBP6 cascade at 525 nm emission,
and (b) the QD655/TMCC1 cascade at 655 nm emission. The three con-
ditions correspond to either target or both targets being present. (c, d)
As (a, b), except against a background of non-target RNA. Results are
normalized to the highest mean FI in the plot. GBP6 (open circles),
TMCC1 (closed circles), GBP6 in presence of TMCC1 (open diamonds)
and TMCC1 in presence of GBP6 (closed diamonds) are represented.
Fig. 2 The dose–response of (a) the QD525s for the GBP6 target and
(b) the QD655s for the TMCC1 target. Fluorescence intensity (FI) of the
QDs is plotted against the concentration of target. Results are normal-
ized to the highest mean FI in the plot.
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of the dose–response curves is well-matched to those con-
ducted in pure buﬀer. This shows that the non-target RNAs are
having little adverse aﬀect on assay function, suggesting that
the two detection cascades (for GBP6 and TMCC1) are func-
tioning independently of one another and of other RNAs
present in the solution.
Assay function in presence of competing targets
The most likely clinical sample to be used in this assay is puri-
fied RNA from whole blood. This will contain a high concen-
tration of other RNA molecules that could interfere with our
detection system. We anticipated that false negatives could be
caused by: (1) other nucleic acids blocking the toehold region
of T*, which would prevent the target RNA from displacing the
QProbe, or (2) other nucleic acids hybridizing to the CProbe or
hybridizing to the QProbe (and thus preventing QProbe hybri-
dizing to CProbe and causing quenching of the QD). This was
investigated by designing GBP6 ‘competing targets’ for the
toehold region of T*, the CProbe and the QProbe.
These competing targets were designed by running a
nucleotide BLAST (basic local alignment search tool) of each
sequence against the Human genomic and transcript data-
base. The result with the highest similarity that was comp-
lementary to the search sequence and that represented a
coding RNA was used to design the competing target. The
region of complementarity shown by the BLAST search
(14–16 bp) was used, and equal sized flanking sequences were
added either side, taken from the transcript sequence in ques-
tion. Each resulting competing target was therefore a 70 nt
RNA molecule. The GBP6 monoplex assay was run in the pres-
ence of 0, 10 or 100 nM of each of these competing targets.
Both T* and CProbe competing targets had a negligible eﬀect
on the dose-response curve for GBP6 target detection (Fig. 4a
and b). At 100 nM QProbe competing target, the dose-response
curve was shifted slightly to the right, indicating that this RNA
molecule was possibly hybridizing to the CProbe and partially
inhibiting QProbe binding (Fig. 4c). However, 100 nM is well
above the actual physiological concentration, so we consider
this not to be problematic.
Sensitivity and specificity
The 50mer target recognition sequences used in these assays
were selected on the basis of their lack of similarity to other
transcripts within the human transcriptome, allowing specific
detection of individual mRNA molecules. For this application,
it is not necessary for the assay to discriminate between tran-
scripts containing single nucleotide polymorphisms. Instead,
we have detected the most biologically realistic interfering case
of competing targets that could interfere with the assay (Fig. 4)
at concentrations well above their physiological concen-
trations. The assay sensitivity required for the detection of
individual transcripts is diﬃcult to determine, especially
because RNA purification yields can vary significantly between
samples. Fortunately, the disease risk score method relies on
the levels of upregulated transcripts compared to the levels of
downregulated transcripts, so endogenous controls or ‘house-
keeping genes’ should not be required when translating this
into a point-of-care test.
Conclusions
In this work, we developed a multiplexed assay capable of
simultaneous detection of targets based on two transcripts
selected from a gene expression signature, combining the
advantages of toehold-mediated strand displacement with
those of QDs to give an assay that is capable of sensitive and
selective detection of synthetic RNA spiked in purified RNA
from whole blood. With reference to the design challenges
that we outlined at the end of the introduction, we explain
how our system overcomes these: (1) the RNA targets do not
come into direct contact with the QDs, which gets rid of steric
hindrance issues and improves assay kinetics for long targets.
(2) The system is completely reliant on highly specific nucleic
acid hybridization and orthogonal cascades that allow for multi-
plexed detection of targets. (3) The detection mechanism on
the surface is not a sandwich-type mechanism, instead the
probe binds with the quencher at the proximal end of the
surface bound duplex, thus maximizing energy transfer and
Fig. 4 Assay performance in the presence of ‘competing targets’ –
derived from BLAST data – that can bind to the (a) T* strand, (b) CProbe
strand or (c) QProbe strand. Fluorescence intensity (FI) of the QDs is
plotted against the concentration of target. Results are normalized to
the highest FI in the plot. 0 nM (light grey circle), 10 nM (grey circle) and
100 nM (black circle) are represented.
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minimizing the LOD of our system. This is a general charac-
teristic that could be further improved using more compact
nanoparticle capping layers. (4) The performance of the assay
in pure buﬀer and against a high background of non-target
RNA is shown to be highly similar, showing that the assay
does not suﬀer from non-specific binding and interference. (5)
The system is homogeneous as no washing or purification
steps are required.
Future high-performance diagnostic tools will likely
combine several key enabling technologies. We envisage our
QD-based toehold-mediated strand displacement assay could
be combined with a simple enzyme-assisted isothermal ampli-
fication mechanism in order to achieve LODs low enough for
direct detection of the target RNA transcripts from RNA iso-
lations from whole blood. The assay that we have described
could serve as a core concept upon which to build an advanced
diagnostic test for TB diagnosis and monitoring.
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